NCT02292225 2023-02-27
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
SecuraBio
Phase 1 Terminated
Clinical Trials
1 trialsHereditary Sensory and Autonomic Neuropathies × obinutuzumab × Other hematologic neoplasm × Clear all